CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF
First Claim
Patent Images
1. A controlled release oral solid formulation of levodopa comprising:
- a. levodopa,b. a decarboxylase inhibitor, andc. a carboxylic acid that is not (a) or (b).
12 Assignments
0 Petitions
Accused Products
Abstract
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
15 Citations
92 Claims
-
1. A controlled release oral solid formulation of levodopa comprising:
-
a. levodopa, b. a decarboxylase inhibitor, and c. a carboxylic acid that is not (a) or (b). - View Dependent Claims (2, 4, 6, 15, 16, 77, 78, 79, 80, 81, 82, 91, 92)
-
-
3. (canceled)
-
5. (canceled)
-
7. (canceled)
-
8. (canceled)
-
9. (canceled)
-
10. (canceled)
-
11. (canceled)
-
12. (canceled)
-
13. (canceled)
-
14. (canceled)
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
-
21. (canceled)
-
22. (canceled)
-
23. (canceled)
-
24. (canceled)
-
25. (canceled)
-
26. (canceled)
-
27. A multiparticulate, controlled release oral solid formulation of levodopa comprising:
-
a. a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; b. a carboxylic acid component; and c. an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. - View Dependent Claims (33, 46, 47, 51, 52)
-
-
28. (canceled)
-
29. (canceled)
-
30. (canceled)
-
31. (canceled)
-
32. (canceled)
-
34. (canceled)
-
35. (canceled)
-
36. (canceled)
-
37. (canceled)
-
38. (canceled)
-
39. (canceled)
-
40. (canceled)
-
41. (canceled)
-
42. (canceled)
-
43. (canceled)
-
44. (canceled)
-
45. (canceled)
-
48. (canceled)
-
49. (canceled)
-
50. (canceled)
-
53. (canceled)
-
54. (canceled)
-
55. A controlled release oral solid formulation of levodopa having a levodopa plasma or serum concentration profile comprising:
-
a. a time of administration, b. a first concentration, and c. a second concentration, wherein, said first concentration is equal to the maximum concentration of said profile;
said second concentration is the minimum concentration occurring at a time later than said first concentration and earlier than or equal to about six hours following said time of administration; and
wherein said second concentration is greater than or equal to about fifty percent of said first concentration.- View Dependent Claims (58)
-
-
56. (canceled)
-
57. (canceled)
-
59. (canceled)
-
60. (canceled)
-
61. (canceled)
-
62. (canceled)
-
63. (canceled)
-
64. (canceled)
-
65. (canceled)
-
66. (canceled)
-
67. (canceled)
-
68. (canceled)
-
69. (canceled)
-
70. (canceled)
-
71. (canceled)
-
72. A controlled release oral solid formulation of levodopa having a median levodopa plasma or serum concentration profile comprising:
-
a. a time of administration; b. a first concentration at a first time, that occurs within one hour of said time of administration; c. a second concentration at a second time, that occurs after said first time; d. a third concentration at a third time, that occurs at least four hours after said second time; wherein, said second concentration is equal to the maximum concentration of said profile;
said first concentration is equal to about fifty percent of said second concentration;
said third concentration is equal to about fifty percent of said second concentration.
-
-
73. A controlled release oral solid formulation having a levodopa plasma or serum concentration profile substantially the same as levodopa formulation IPX066 in
FIG. 1 for a 380 mg dose of levodopa, or having a levodopa plasma or serum concentration profile substantially proportional to said formulation inFIG. 1 for a dose other than 380 mg.
-
74. A controlled release oral solid formulation having a levodopa plasma or serum concentration profile such that the ratio of the maximum concentration of said profile to the concentration at any time between one hour and seven hours after administration of said formulation is less than or equal to 4:
- 1.
-
75. A controlled release oral solid formulation of levodopa having a median levodopa plasma or serum concentration profile comprising:
-
a. a first concentration at a first time; b. a second concentration at a second time, that occurs within about one hour after said first time; c. a third concentration at a third time, that occurs at least four hours after said second time; and d. a maximum concentration, wherein, said second concentration is equal to the maximum concentration of said profile;
said first concentration is equal to fifty percent of said second concentration;
said third concentration is equal to fifty percent of said second concentration.
-
-
76. A stable, controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor and a dicarboxylic acid wherein no more than 1% by weight of the degradation product of levodopa is present after being stored for 3 months at 40 degrees Centigrade and 75% relative humidity.
-
83. (canceled)
-
84. (canceled)
-
85. (canceled)
-
86. (canceled)
-
87. (canceled)
-
88. (canceled)
-
89. (canceled)
-
90. (canceled)
Specification